DEPOCYT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depocyt, and when can generic versions of Depocyt launch?
Depocyt is a drug marketed by Pacira Pharms Inc and is included in one NDA.
The generic ingredient in DEPOCYT is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depocyt
A generic version of DEPOCYT was approved as cytarabine by HIKMA on August 2nd, 1989.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPOCYT?
- What are the global sales for DEPOCYT?
- What is Average Wholesale Price for DEPOCYT?
Summary for DEPOCYT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Clinical Trials: | 79 |
| Patent Applications: | 4,457 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DEPOCYT |
| DailyMed Link: | DEPOCYT at DailyMed |
Recent Clinical Trials for DEPOCYT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
| University of Florida | Phase 2 |
| Medical College of Wisconsin | Phase 1 |
US Patents and Regulatory Information for DEPOCYT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPOCYT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for DEPOCYT
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pacira Limited | DepoCyte | cytarabine | EMEA/H/C/000317 Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease. |
Withdrawn | no | no | no | 2001-07-11 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DEPOCYT
See the table below for patents covering DEPOCYT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 60127134 | ⤷ Sign Up | |
| Israel | 131012 | ⤷ Sign Up | |
| Australia | 1205588 | ⤷ Sign Up | |
| Japan | 5441966 | ⤷ Sign Up | |
| European Patent Office | 1307232 | COMPOSITION POUR L'ADMINISTRATION TRANSDERMIQUE ET/OU TRANSMUQUEUSE DE COMPOSES ACTIFS ASSURANT DES NIVEAUX D'EFFICACITE THERAPEUTIQUE ADEQUATS (NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS) | ⤷ Sign Up |
| Portugal | 86805 | PROCESSO PARA A PREPARACAO DE COMPOSICOES FARMACEUTICAS CONTENDO PRINCIPIOS ACTIVOS ENCAPSULADOS NA PRESENCA DE UM CLORIDRATO EM LIPOSOMAS MULTIVESICULARES | ⤷ Sign Up |
| Australia | 2004283431 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEPOCYT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1744764 | 2018C/045 | Belgium | ⤷ Sign Up | PRODUCT NAME: VYXEOS (DAUNORUBICINE/CYTARABINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180823 |
| 1744764 | SPC/GB18/045 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308/001-003 20180827; UK PLGB 31626/0004 20180827 |
| 3300601 | 2290030-2 | Sweden | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180827 |
| 1744764 | 2018/042 | Ireland | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| 2768484 | LUC00135 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
| 2768484 | 2019C/545 | Belgium | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
| 1744764 | 300960 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
